Last reviewed · How we verify

Teneligliptin/Canagliflozin — Competitive Intelligence Brief

Teneligliptin/Canagliflozin (Teneligliptin/Canagliflozin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor, SGLT2 inhibitor. Area: Diabetes.

phase 3 DPP-4 inhibitor, SGLT2 inhibitor DPP-4, SGLT2 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Teneligliptin/Canagliflozin (Teneligliptin/Canagliflozin) — Tanabe Pharma Corporation. Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Teneligliptin/Canagliflozin TARGET Teneligliptin/Canagliflozin Tanabe Pharma Corporation phase 3 DPP-4 inhibitor, SGLT2 inhibitor DPP-4, SGLT2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor, SGLT2 inhibitor class)

  1. Tanabe Pharma Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Teneligliptin/Canagliflozin — Competitive Intelligence Brief. https://druglandscape.com/ci/teneligliptin-canagliflozin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: